Literature DB >> 20405349

Evaluation of FAK and Src expression in human benign and malignant thyroid lesions.

Christina Michailidi1, Costas Giaginis, Vassilios Stolakis, Paraskevi Alexandrou, Jerzy Klijanienko, Ioanna Delladetsima, Nicolaos Chatzizacharias, Gerasimos Tsourouflis, Stamatios Theocharis.   

Abstract

Focal Adhesion Kinase (FAK) and Src have been reported to regulate tumor growth, invasion, metastasis and angiogenesis. The present study aimed to evaluate by immunohistochemistry the clinical significance of FAK and Src expression in 108 patients with benign and malignant thyroid lesions. Total FAK expression provided a distinct discrimination between malignant and benign (p = 0.00001), as well as between papillary carcinoma and hyperplastic nodules thyroid lesions (p = 0.00005), being also associated with follicular cells' proliferative capacity (p = 0.0003). In malignant thyroid lesions, total FAK expression was associated with tumor size (p = 0.0455), and presence of capsular (p = 0.0102) and lymphatic (p = 0.0173) invasion. Total Src expression was borderline increased in cases of papillary carcinoma compared to hyperplastic nodules (p = 0.0993), being also correlated with tumor size (p = 0.0169). FAK and Src expression was ascribed to a significant extent to the phosphorylated forms of the enzymes, which provided a better discrimination between malignant and benign thyroid lesions. The current data revealed that FAK and to a lesser extent Src expression could be considered of clinical utility in thyroid neoplasia with potential use as therapeutic targets.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20405349     DOI: 10.1007/s12253-010-9269-3

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  48 in total

Review 1.  Signaling through focal adhesion kinase.

Authors:  D D Schlaepfer; C R Hauck; D J Sieg
Journal:  Prog Biophys Mol Biol       Date:  1999       Impact factor: 3.667

2.  Focal adhesion kinase as a marker of invasive potential in differentiated human thyroid cancer.

Authors:  L V Owens; L Xu; G A Dent; X Yang; G C Sturge; R J Craven; W G Cance
Journal:  Ann Surg Oncol       Date:  1996-01       Impact factor: 5.344

3.  Fluid shear stress activation of focal adhesion kinase. Linking to mitogen-activated protein kinases.

Authors:  S Li; M Kim; Y L Hu; S Jalali; D D Schlaepfer; T Hunter; S Chien; J Y Shyy
Journal:  J Biol Chem       Date:  1997-11-28       Impact factor: 5.157

4.  Bombesin, vasopressin, and endothelin stimulation of tyrosine phosphorylation in Swiss 3T3 cells. Identification of a novel tyrosine kinase as a major substrate.

Authors:  I Zachary; J Sinnett-Smith; E Rozengurt
Journal:  J Biol Chem       Date:  1992-09-25       Impact factor: 5.157

5.  GABA receptor expression in benign and malignant thyroid tumors.

Authors:  Stephen S Roberts; Maria Cecilia Mendonça-Torres; Kirk Jensen; Gary L Francis; Vasyl Vasko
Journal:  Pathol Oncol Res       Date:  2009-04-19       Impact factor: 3.201

Review 6.  Disruption of FAK signaling: a side mechanism in cytotoxicity.

Authors:  Nikolaos A Chatzizacharias; Gregory P Kouraklis; Stamatios E Theocharis
Journal:  Toxicology       Date:  2007-12-15       Impact factor: 4.221

7.  Biological significance of focal adhesion kinase in ovarian cancer: role in migration and invasion.

Authors:  Anil K Sood; Jeremy E Coffin; Galen B Schneider; Mavis S Fletcher; Barry R DeYoung; Lynn M Gruman; David M Gershenson; Michael D Schaller; Mary J C Hendrix
Journal:  Am J Pathol       Date:  2004-10       Impact factor: 4.307

8.  The significance of Galectin-3 expression in the immunocytochemical evaluation of thyroid fine needle aspiration cytology.

Authors:  Safak Ersoz; Hikmet Sert; Mustafa Yandi; Cihangir Erem; Sevdegul Mungan; Halil Onder Ersoz; Umit Cobanoglu; Arif Hacihasanoglu
Journal:  Pathol Oncol Res       Date:  2008-04-16       Impact factor: 3.201

9.  Reduced expression of focal adhesion kinase in intrahepatic cholangiocarcinoma is associated with poor tumor differentiation.

Authors:  Ryuji Ohta; Yo-ichi Yamashita; Akinobu Taketomi; Dai Kitagawa; Yosuke Kuroda; Shinji Itoh; Shin-ichi Aishima; Yoshihiko Maehara
Journal:  Oncology       Date:  2007-08-08       Impact factor: 2.935

10.  Increase in activity and level of pp60c-src in progressive stages of human colorectal cancer.

Authors:  M S Talamonti; M S Roh; S A Curley; G E Gallick
Journal:  J Clin Invest       Date:  1993-01       Impact factor: 14.808

View more
  12 in total

Review 1.  Thyroid hormone receptors and cancer.

Authors:  Won Gu Kim; Sheue-yann Cheng
Journal:  Biochim Biophys Acta       Date:  2012-04-06

2.  SKI-606, an Src inhibitor, reduces tumor growth, invasion, and distant metastasis in a mouse model of thyroid cancer.

Authors:  Won Gu Kim; Celine J Guigon; Laura Fozzatti; Jeong Won Park; Changxue Lu; Mark C Willingham; Sheue-yann Cheng
Journal:  Clin Cancer Res       Date:  2012-01-23       Impact factor: 12.531

3.  Elevated Hu-Antigen Receptor (HuR) Expression is Associated with Tumor Aggressiveness and Poor Prognosis but not with COX-2 Expression in Invasive Breast Carcinoma Patients.

Authors:  Constantinos Giaginis; Anastasia Sampani; Iolly Kotta-Loizou; Ioanna Giannopoulou; Eugene Danas; Ekaterini Politi; Gerasimos Tsourouflis; Gregorios Kouraklis; Efstratios Patsouris; Antonios Keramopoulos; Lydia Nakopoulou; Stamatios Theocharis
Journal:  Pathol Oncol Res       Date:  2017-08-14       Impact factor: 3.201

4.  Overexpression of epidermal growth factor receptor and its downstream effector, focal adhesion kinase, correlates with papillary thyroid carcinoma progression.

Authors:  Sonja Šelemetjev; Aleksandar Bartolome; Tijana Išić Denčić; Ilona Đorić; Ivan Paunović; Svetislav Tatić; Dubravka Cvejić
Journal:  Int J Exp Pathol       Date:  2018-04-17       Impact factor: 1.925

5.  FAK and Src expression in mobile tongue squamous cell carcinoma: associations with clinicopathological parameters and patients survival.

Authors:  Stamatios Theocharis; Jerzy Klijanienko; Constantinos Giaginis; Paraskevi Alexandrou; Efstratios Patsouris; Xavier Sastre-Garau
Journal:  J Cancer Res Clin Oncol       Date:  2012-04-10       Impact factor: 4.553

6.  Clinical significance of histone deacetylase (HDAC)-1, HDAC-2, HDAC-4, and HDAC-6 expression in human malignant and benign thyroid lesions.

Authors:  Constantinos Giaginis; Paraskevi Alexandrou; Ioanna Delladetsima; Ioanna Giannopoulou; Efstratios Patsouris; Stamatios Theocharis
Journal:  Tumour Biol       Date:  2013-07-20

7.  Phosphorylated c-Src is a novel predictor for recurrence in cervical squamous cell cancer patients.

Authors:  Teng Hou; Juan Xiao; Huiting Zhang; Haifeng Gu; Yanling Feng; Jundong Li
Journal:  Int J Clin Exp Pathol       Date:  2013-05-15

8.  FAK Expression, Not Kinase Activity, Is a Key Mediator of Thyroid Tumorigenesis and Protumorigenic Processes.

Authors:  Brittelle E Kessler; Vibha Sharma; Qiong Zhou; Xia Jing; Laura A Pike; Anna A Kerege; Sharon B Sams; Rebecca E Schweppe
Journal:  Mol Cancer Res       Date:  2016-06-03       Impact factor: 5.852

9.  Clinical Significance of Hu-Antigen Receptor (HuR) and Cyclooxygenase-2 (COX-2) Expression in Human Malignant and Benign Thyroid Lesions.

Authors:  Constantinos Giaginis; Paraskevi Alexandrou; Ioanna Delladetsima; Ioannis Karavokyros; Eugene Danas; Athina Giagini; Efstratios Patsouris; Stamatios Theocharis
Journal:  Pathol Oncol Res       Date:  2016-01       Impact factor: 3.201

10.  Combined BRAF(V600E)- and SRC-inhibition induces apoptosis, evokes an immune response and reduces tumor growth in an immunocompetent orthotopic mouse model of anaplastic thyroid cancer.

Authors:  Pierre Vanden Borre; Viswanath Gunda; David G McFadden; Peter M Sadow; Shohreh Varmeh; Maria Bernasconi; Sareh Parangi
Journal:  Oncotarget       Date:  2014-06-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.